FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Comments Sought on WHO Drug Scheduling

[ Price : $8.95]

Federal Register notice: FDA provides an opportunity to submit written comments on recommendations by the World Health Organizatio...

Eisai Expects FDA to Approve Alzheimers Drug Soon

[ Price : $8.95]

Eisai CEO Ivan Cheung says he expects full FDA approval for the early Alzheimers drug Leqembi by this summer if the agency gives t...

FDA OKs Chiesis Lamzede for Alpha-Mannosidosis

[ Price : $8.95]

FDA approves Chiesis Lamzede to treat some manifestations of alpha-mannosidosis in adults and children.

FDA Withdraws Miles Laboratories ANDA

[ Price : $8.95]

Federal Register notice: FDA withdraws a Miles Laboratories ANDA for alcohol and dextrose injection, 5 mL/100 mL because the agenc...

Product-Specific Guidance Meetings

[ Price : $8.95]

FDA publishes a draft guidance with information on requesting and conducting product-specific guidance meetings between FDA and AN...

Califf Sees Misinformation as Cause of Preventable Deaths

[ Price : $8.95]

FDA commissioner Robert Califf announces a project to explore ways the agency can respond to and counter misleading health informa...

Zephyrus Safety Syringe Cleared

[ Price : $8.95]

FDA clears a Zephyrus Innovations 510(k) for its Aerojec 3ml safety syringe.

FDA OKs Apellis Syfovre for Geographic Atrophy

[ Price : $8.95]

FDA approves Apellis Pharmaceuticals Syfovre to treat geographic atrophy secondary to age-related macular degeneration.

Guide on Compounding Ibuprofen Oral Suspension

[ Price : $8.95]

Federal Register notice: FDA makes available a final guidance on compounding certain ibuprofen oral suspension products.

2 Meetings on Adverse Event Reporting

[ Price : $8.95]

Federal Register notice: FDA announces two public meetings on electronic submission of adverse event reports using International C...